Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;95(11):e29244.
doi: 10.1002/jmv.29244.

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Sebastian O Wendel  1 , Jazmine A Snow  1 , Long Gu  2 , Nilam Sanjib Banerjee  3 , Linda Malkas  2 , Nicholas A Wallace  1
Affiliations
Review

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

Sebastian O Wendel et al. J Med Virol. 2023 Nov.

Abstract

Cervical cancers are the fourth most common and most deadly cancer in women worldwide. Despite being a tremendous public health burden, few novel approaches to improve care for these malignancies have been introduced. We discuss the potential for proliferating cell nuclear antigen (PCNA) inhibition to address this need as well as the advantages and disadvantages for compounds that can therapeutically inhibit PCNA with a specific focus on cervical cancer.

Keywords: chemotherapy; disease control; human papillomavirus; oncogenesis; virus classification.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: The authors declare the following competing financial interest(s): City of Hope’s Office of Technology Licensing has been awarded a patent on AOH1996 and its analogs. L.H. Malkas, R.J. Hickey, D. Horne, and L. Gu are listed as inventors. Received: May 12, 2022; Revised: February 12, 2023; Accepted: July 10, 2023; Published: August 1, 2023.

Figures

Figure 1:
Figure 1:
Nucleoside supplementation reduces cisplatin toxic in CaCx cells. HeLa cells were exposed to a gradient of cisplatin concentrations either with or without nucleoside supplementation to lower replication stress in these cells. Relative viability was determined by MTT assay. * and ** indicate statistically significant differences in viability at indicated points (p <0.05 and < 0.01, respectively).
See this image and copyright information in PMC

References

    1. Van Doorslaer K, Li Z, Xirasagar S, et al. The Papillomavirus Episteme: a major update to the papillomavirus sequence database. Nucleic Acids Res. 2017;45(Database issue):D499–D506. doi:10.1093/nar/gkw879 - DOI - PMC - PubMed
    1. WHO | Human papillomavirus (HPV) and cervical cancer. WHO. Published November 18, 2016. Accessed November 18, 2016. http://www.who.int/mediacentre/factsheets/fs380/en/
    1. Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: A review. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2011;51(2):103–108. doi:10.1111/j.1479-828X.2010.01269.x - DOI - PubMed
    1. Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases. Cancer. 2017;123(12):2219–2229. doi:10.1002/cncr.30588 - DOI - PubMed
    1. Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. The Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X - DOI - PubMed

Publication types

MeSH terms

Substances